

OCT 20 2000 C-1  
PATENT TRADEMARK OFFICE  
RECEIVED

RECEIVED  
OCT 30 2000 116  
TECH CENTER 1600/2900

THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the Application of:  
Kenneth Brasel et al.

Docket No.: 2836-D

Serial No: 09/448,378

Group Art Unit: 1644

Filed: November 23, 1999

Examiner: F. VanderVegt

For: DENDRITIC CELL STIMULATORY  
FACTOR

RECEIVED

NOV 06 2000

AMENDMENT AND RESPONSE

TECH CENTER 1600/2900

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

In response to the Office Action mailed July 17, 2000, (Paper No. 5), and pursuant to Rule 111 of the Rules of Practice, Applicants offer the following remarks and amendments. Reconsideration of the above-captioned application is respectfully requested. Applicants enclose herewith enclose a copy of U.S. Patent No. 5,554,512, and a sequence listing in both paper copy and computer-readable form.

AMENDMENTS

*In the specification:*

Please enter the enclosed sequence listing into the file of the application.

At page 8, line 16, please delete the text of this line and insert therefore the following replacement text:

--reference. Anti-CD34 is commercially available from Becton Dickinson (Franklin Lakes,--.

*In the claims:*

Please cancel claims 1 and 2, without prejudice.

In claims 28, 30, 37 and 39, please delete "SEQ ID NO:2" and replace therefore --SEQ ID NO:1--.

In claims 27 and 29, please amend the claims to depend upon claim 6, and delete the term "soluble human".